vTv Therapeutics appoints Paul Sekhri as President and CEO effective August 1, 2022

vTv Therapeutics Inc.

Paul Sekhri appointed President and CEO effective Aug 1, 2022; succeeds Richard Nelson, who becomes EVP and remains on board.
Employment terms: $480k base salary, 75% bonus target, 2.2M stock options at $0.79/share (NASDAQ inducement grant).
Options vest 25% after one year, then quarterly over three years; accelerated vesting on certain performance metrics.
Severance: 12 months base (18 months post-change of control), COBRA, target bonus; two-year non-compete and non-solicit.
vTv is preparing Phase 3 trials for TTP399 (type 1 diabetes) with recent $25M G42 investment and Breakthrough Therapy designation.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Richard S. Nelson

Executive Vice President

VTVT · vTv Therapeutics Inc.

Effective: 2022-08-01
Successor: Paul Sekhri
Filed: July 27, 2022, 7:59 PM ET

As of the Effective Date, Richard S. Nelson will cease to be the Interim Chief Executive Officer but will continue to serve as a member of the Board and as an Executive Vice President of the Company.

Appointed

Paul Sekhri

President and Chief Executive Officer

VTVT · vTv Therapeutics Inc.

Effective: 2022-08-01
Filed: July 27, 2022, 7:59 PM ET

On July 27, 2022, vTv Therapeutics Inc. (the “Company”) announced that the board of directors of the Company (the “Board”) has appointed Paul Sekhri as President and Chief Executive Officer and as a member of the Board, effective as of August 1, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard S. Nelson changed role as Executive Vice President at vTv Therapeutics Inc..

Action: ceased to be Interim Chief Executive Officer
Role: Executive Vice President

Exact text from the filing

As of the Effective Date, Richard S. Nelson will cease to be the Interim Chief Executive Officer but will continue to serve as a member of the Board and as an Executive Vice President of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Paul Sekhri was appointed as President and Chief Executive Officer at vTv Therapeutics Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On July 27, 2022, vTv Therapeutics Inc. (the “Company”) announced that the board of directors of the Company (the “Board”) has appointed Paul Sekhri as President and Chief Executive Officer and as a member of the Board, effective as of August 1, 2022

View on SEC.gov

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0000950142-22-002314

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.